| pubmed-article:3263103 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3263103 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:3263103 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:3263103 | lifeskim:mentions | umls-concept:C0024348 | lld:lifeskim |
| pubmed-article:3263103 | lifeskim:mentions | umls-concept:C1444748 | lld:lifeskim |
| pubmed-article:3263103 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:3263103 | pubmed:dateCreated | 1988-11-7 | lld:pubmed |
| pubmed-article:3263103 | pubmed:abstractText | Cytolytic T lymphocytes (CTLs) are an efficient immune mechanism for the destruction of foreign or pathogenic cells. Attempts to use CTLs in human cancer therapy have focused on the cell-surface molecules that regulate CTL function. An important molecule in CTL function is the CD3 antigen. Biochemical characterization has suggested that the CD3 antigen may function as a "trigger" for T-lymphocyte activation. To investigate this possibility, we used monoclonal antibody (MAb) to the CD3 antigen to trigger activation of long-term CTL lines. The anti-CD3 MAb was able to trigger killing of a variety of human and mouse tumor cell lines; however, not all tumor cells were lysed by the CTL. The susceptibility of the tumor cells to CTL-mediated lysis appeared to correlate with the binding of the anti-CD3 MAb to the tumor cell surface. The requirement for surface binding of the MAb was tested by covalently cross-linking the anti-CD3 MAb to the tumor cell membrane. Membrane-bound anti-CD3 MAb triggered high levels of CTL-mediated tumor cell killing. Similar results were obtained when anti-CD3 MAb was cross-linked to phosphatidylethanolamine and inserted into the cell membrane. These results indicate that the attachment of anti-CD3 MAb to the tumor cell surface provides a powerful new approach to the in vitro activation of human killer T cells and the in vivo treatment of human cancer. | lld:pubmed |
| pubmed-article:3263103 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3263103 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3263103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3263103 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3263103 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:3263103 | pubmed:issn | 0004-0010 | lld:pubmed |
| pubmed-article:3263103 | pubmed:author | pubmed-author:WilsonR ERE | lld:pubmed |
| pubmed-article:3263103 | pubmed:author | pubmed-author:BurakoffS JSJ | lld:pubmed |
| pubmed-article:3263103 | pubmed:author | pubmed-author:MentzerS JSJ | lld:pubmed |
| pubmed-article:3263103 | pubmed:author | pubmed-author:HerrmannS HSH | lld:pubmed |
| pubmed-article:3263103 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3263103 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:3263103 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3263103 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3263103 | pubmed:pagination | 1280-5 | lld:pubmed |
| pubmed-article:3263103 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:meshHeading | pubmed-meshheading:3263103-... | lld:pubmed |
| pubmed-article:3263103 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3263103 | pubmed:articleTitle | Membrane-bound anti-CD3 monoclonal antibodies trigger cytolytic T-lymphocyte-mediated tumor lysis. | lld:pubmed |
| pubmed-article:3263103 | pubmed:affiliation | Department of Surgery, Brigham and Women's Hospital, Boston, MA. | lld:pubmed |
| pubmed-article:3263103 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3263103 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
